Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.56 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.56 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.56 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.56 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 2/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4409891 | 0.82 | PI4KA (0.55) | PI4KAPI4K2BPI4K2API4KBPDE2A | |
| SCHEMBL17889388 | 0.81 | PDE2A (0.47) | PI4KAPI4K2BPI4K2API4KBPDE2A | |
| SCHEMBL128577 | 0.81 | PI4KA (0.53) | PI4KAPI4K2BPI4K2API4KBPDE2A | |
| SCHEMBL130798 | 0.81 | PI4KA (0.53) | PI4KAPI4K2BPI4K2API4KBPDE2A | |
| SCHEMBL29685062 | 0.81 | PDE2A (0.60) | PI4KAPI4K2BPI4K2API4KBPDE2A | |
| SCHEMBL130521 | 0.81 | PDE2A (0.60) | PI4KAPI4K2BPI4K2API4KBPDE2A | |
| SCHEMBL21282826 | 0.78 | PI4KA (0.50) | PI4KAPI4K2BPI4K2API4KBPDE2A | |
| SCHEMBL26973527 | 0.78 | PI4KA (0.50) | PI4KAPI4K2BPI4K2API4KBPDE2A | |
| SCHEMBL29385938 | 0.78 | PI4KA (0.50) | PI4KAPI4K2BPI4K2API4KBPDE2A | |
| SCHEMBL13082325 | 0.78 | MEN1 (0.46) | PI4KAPI4K2BPI4K2API4KBPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3986568-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OFBCDIN3D ACTIVITY | Storm Therapeutics Ltd (GB) | 2022-04-27 | — | — | EP | claimed |
| CN-114286711-A | Bicyclic heterocyclic compounds as inhibitors of BCDIN3D activity | 风暴治疗有限公司 | 2022-04-05 | — | — | CN | claimed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| EP-4234565-A2 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | ATEA Pharmaceuticals, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11738038-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| EP-3727389-B1 | COMPOUNDS AS MTOR INHIBITORS | GALDERMA RES & DEV (FR) | 2023-05-03 | — | — | EP | disclosed |
| US-20220370453-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BCDIN3D ACTIVITY | STORM THERAPEUTICS LIMITED (GB) | 2022-11-24 | — | — | US | disclosed |
| EP-3986568-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OFBCDIN3D ACTIVITY | Storm Therapeutics Ltd (GB) | 2022-04-27 | — | — | EP | disclosed |
| CN-114286711-A | Bicyclic heterocyclic compounds as inhibitors of BCDIN3D activity | 风暴治疗有限公司 | 2022-04-05 | — | — | CN | disclosed |
| US-11020399-B2 | Intermediates useful in the synthesis of compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2021-06-01 | — | — | US | disclosed |
| US-10442783-B2 | 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-10-15 | — | — | US | disclosed |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2012-03-08 | — | — | US | disclosed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | disclosed |
| US-7718374-B2 | Single nucleotide polymorphism analysis of highly polymorphic target sequences | ELITECH HOLDING B.V. (NL) | 2010-05-18 | — | — | US | disclosed |
| US-20090087922-A1 | SINGLE NUCLEOTIDE POLYMORPHISM ANALYSIS OF HIGHLY POLYMORPHIC TARGET SEQUENCES | EPOCH BIOSCIENCES, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| US-7348146-B2 | Single nucleotide polymorphism analysis of highly polymorphic target sequences | EPOCH BIOSCIENCES, INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-20070037977-A1 | Substituted-1, 3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | BELLEAU BERNARD | 2007-02-15 | — | — | US | disclosed |
| US-20070037977-A1 | Substituted-1, 3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | BELLEAU BERNARD | 2007-02-15 | — | — | US | disclosed |
| US-20070037975-A1 | Substituted-1,3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | BELLEAU BERNARD | 2007-02-15 | — | — | US | disclosed |
| US-20070037975-A1 | Substituted-1,3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | BELLEAU BERNARD | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442783-B2 | 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases | PIK3CB, PIK3CD, PDPK1 | PI4KA 35/4885PI4K2B 51/4885PI4K2A 46/4885 |
| US-11020399-B2 | Intermediates useful in the synthesis of compounds as modulators of protein kinases | MAP4K2, MAP3K20, MAP3K1 | PI4KA 217/4885PI4K2B 228/4885PI4K2A 236/4885 |
| US-20070037977-A1 | Substituted-1, 3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | IFNAR1, MAVS, IFNG | PI4KA 2118/4885PI4K2B 2686/4885PI4K2A 2535/4885 |
| US-20070037975-A1 | Substituted-1,3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | IFNAR1, MAVS, IFNG | PI4KA 2306/4885PI4K2B 2854/4885PI4K2A 2717/4885 |
| US-11738038-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | PI4KA 2231/4885PI4K2B 2181/4885PI4K2A 2087/4885 |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | PI4KA 98/4885PI4K2B 82/4885PI4K2A 87/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | PI4KA 156/4885PI4K2B 140/4885PI4K2A 143/4885 |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | PI4KA 98/4885PI4K2B 82/4885PI4K2A 87/4885 |
| US-20220370453-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BCDIN3D ACTIVITY | BCDIN3D, CDK3, CCNI | PI4KA 2759/4885PI4K2B 3097/4885PI4K2A 3501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.